Insider Transactions in Q4 2021 at Monopar Therapeutics (MNPR)
Insider Transaction List (Q4 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 31
2021
|
Arthur J Klausner Director |
BUY
Exercise of conversion of derivative security
|
Direct |
751
+7.48%
|
-
|
|
Dec 31
2021
|
Christopher M Starr Director |
BUY
Exercise of conversion of derivative security
|
Direct |
751
+14.89%
|
-
|
|
Dec 31
2021
|
Michael J Brown Director |
BUY
Exercise of conversion of derivative security
|
Direct |
751
+0.35%
|
-
|
|
Dec 31
2021
|
Raymond Anderson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
751
+12.42%
|
-
|
|
Dec 31
2021
|
Chandler Robinson Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,364
-4.44%
|
$4,092
$3.21 P/Share
|
|
Dec 31
2021
|
Chandler Robinson Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,941
+11.38%
|
-
|
|
Dec 31
2021
|
Kim R Tsuchimoto Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
501
-10.68%
|
$1,503
$3.21 P/Share
|
|
Dec 31
2021
|
Kim R Tsuchimoto Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,221
+20.66%
|
-
|
|
Dec 31
2021
|
Andrew Paul Mazar Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
556
-2.74%
|
$1,668
$3.21 P/Share
|
|
Dec 31
2021
|
Andrew Paul Mazar Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,606
+7.34%
|
-
|